Literature DB >> 11338475

Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization.

L Wilkens1, M Bredt, P Flemming, S Kubicka, J Klempnauer, H Kreipe.   

Abstract

Fibrolamellar hepatocellular carcinoma (FLC) is a rare entity of hepatocellular carcinoma (HCC) not yet analyzed cytogenetically. By using comparative genomic hybridization (CGH), we looked for chromosome changes in 2 primary FLCs and a recurrent FLC with and without metastases. CGH revealed an amplification of 1q in 1 primary FLC. The other primary FLC and a metastasis revealed no changes. The recurrent FLC showed 18 aberrations, including 1q+, 2p+, 3p+, 3q+, 4p+, 4q+, 5p+, 5q+, 6q+, 8p+, 8q+, 9q+, 12p+, 12q+, 18p+, 18q+, Xp+, and Xq+. In 2 metastases, 9 and 10 aberrations were seen, including 1q+, 3p-, 3q-, 4q+, 5p+, 5q+, 8q+, 10p+, 10q+, Xp+, and Xq+. In 9 cases of other entities of HCC, a mean of 10.2 aberrations per case were detectable affecting 1q (7 cases), 4q (5), 5q (4), 6q (5), 8p (5), 8q (5), 9p (4), 9q (5), 16q (4), 17p (5), and 17q (4). Chromosomes 2p, 2q, 3p, 3q, 4p, 5p, 6p, 7p, 7q, 10q, 11p, 11q, 12p, 12q, 13q, 14q, 16p, 18p, 18q, 20p, 20q, and 21q were altered in up to 3 samples. Our findings indicate striking differences in the number of chromosomal imbalances in primary FLC and recurrent FLC, whereas imbalances seen in the recurrent FLC and the other entities of HCC were similar in number and chromosomes involved. It may be speculated that these aberrations represent secondary events based on a genetic instability and do not mirror the primary alterations in these carcinomas.

Entities:  

Mesh:

Year:  2000        PMID: 11338475     DOI: 10.1309/BMTT-JBPD-D13H-1UVD

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  16 in total

1.  The abnormalities of chromosome 8 in two hepatocellular carcinoma cell clones with the same genetic background and different metastatic potential.

Authors:  Jiong Yang; Lun-Xiu Qin; Sheng-Long Ye; Yin-Kun Liu; Yan Li; Dong-Mei Gao; Jie Chen; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-15       Impact factor: 4.553

2.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

3.  Cell cycle biology of fibrolamellar hepatocellular carcinoma.

Authors:  Sadhna Dhingra; Wei Li; Dongfeng Tan; Maryam Zenali; Haizeng Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-11-02

4.  The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.

Authors:  Prasanna K Santhekadur; Devaraja Rajasekaran; Ayesha Siddiq; Rachel Gredler; Dong Chen; Scott E Schaus; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

5.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

7.  Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas.

Authors:  Tasneem Motiwala; Kalpana Ghoshal; Anindita Das; Sarmila Majumder; Dieter Weichenhan; Yue-Zhong Wu; Kristen Holman; S Jill James; Samson T Jacob; Christoph Plass
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

8.  CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.

Authors:  Jian Hong; Kaishun Hu; Yunfei Yuan; Yi Sang; Qiangui Bu; Guihua Chen; Longjun Yang; Binkui Li; Pinzhu Huang; Dongtai Chen; Yi Liang; Ruhua Zhang; Jingxuan Pan; Yi-Xin Zeng; Tiebang Kang
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

Review 9.  Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Authors:  Gadi Lalazar; Sanford M Simon
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

10.  Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma.

Authors:  Byoung Kwon Yoo; Luni Emdad; Rachel Gredler; Christine Fuller; Catherine I Dumur; Kimberly H Jones; Colleen Jackson-Cook; Zao-Zhong Su; Dong Chen; Utsav H Saxena; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.